Aptadir Therapeutics

RNA molecules that target DNA methylation

Aptadir’s DiR platform is based on DNMT-interacting RNAs. Its aptaDiR molecules bind and inhibit DNMT1, while captaDiR fuses the RNA inhibitor to a gene-specific sequence to target DNA methylation at an individual locus. The approach aims to reactivate genes that have been silenced in disease, rather than broadly altering methylation across the genome.

A pipeline led by Fragile X syndrome

The company’s lead investigational program, CAP1-FMR1, is being developed for Fragile X syndrome, where the FMR1 gene is silenced. Aptadir’s pipeline also covers other rare genetic disorders and cancers. Investor and company materials describe the company as preclinical; these are development-stage therapeutics, not approved or clinically available treatments.

Platform: DNMT-interacting RNAs (DiRs)
Lead program: CAP1-FMR1 for Fragile X syndrome
Stage: Preclinical

Funding history

1 round · 1 with disclosed amounts

Announced	Round	Amount	Investors
Sep 29, 2026	Seed	€40M	4BIO Capital — LeadAngelini Ventures — ParticipantBio Lombardia Fund — ParticipantCDP Venture Capital — ParticipantCE-Ventures — ParticipantClub degli Investitori — ParticipantEXTEND Initiative — ParticipantIndaco Bio — ParticipantItalian Angels for Biotech — ParticipantKerna Ventures — ParticipantXgen Ventures — Participant